基于RNA的结直肠癌疗法(综述)
创作:szx 审核:szx 01月06日
  • 基于RNA的治疗结直肠癌的策略主要有6种;
  • 包括:利用siRNA或miRNA对特定基因进行RNA干扰,利用反义寡核苷酸靶向特定mRNA、miRNA或pre-mRNA,利用可形成三维结构的RNA适配体靶向结合蛋白、多肽或小分子;
  • 以及:利用设计的核糖酶调控靶基因表达,利用长非编码RNA调控靶基因表达,利用小激活RNA(saRNA)激活抑癌基因的转录;
  • 目前尚无基于RNA治疗结直肠癌的疗法获批;
  • 基于RNA的疗法仍面临诸多挑战,如脱靶效应、组织分布、靶点鉴定等。
主编推荐语
szx
Pharmacological Research上发表的一篇综述文章,详细介绍了6种不同的基于RNA的结直肠癌治疗策略,并讨论了基于RNA的疗法所具有的优势及面临的挑战。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!

RNA-based therapeutics for colorectal cancer: updates and future directions

基于RNA的结直肠癌疗法:最新进展与未来方向

10.1016/j.phrs.2019.104550

2019-12-19, Review

Abstract & Authors:展开

Abstract:收起
Colorectal cancer (CRC) is one of the most common causes of cancer death worldwide. While standard chemotherapy and new targeted therapy have been improved recently, problems such as multidrug resistance (MDR) and severe side effects remain unresolved. RNAs are essential to all biological processes including cell proliferation and differentiation, cell cycle, apoptosis, activation of tumor suppressor genes, suppression of oncogenes. Therefore, there are various potential approaches to address genetic disease like CRC at the RNA level. In contrast to conventional treatments, RNA-based therapeutics such as RNA interference, antisense oligonucleotides, RNA aptamer, ribozymes, have the advantages of high specificity, high potency and low toxicity. It has gained more and more attention due to the flexibility in modulating a wide range of targets. Here, we highlight recent advances and clinical studies involving RNA-based therapeutics and CRC. We also discuss their advantages and limitations that remain to be overcome for the treatment of human CRC.

First Authors:
Jingwen Liu,Bin Guo

Correspondence Authors:
Jingwen Liu,Bin Guo

All Authors:
Jingwen Liu,Bin Guo

评论